- Home
- IFRX vs NNBR Comparison
IFRX vs NNBR Comparison
Compare IFRX & NNBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- NNBR
- Stock Information
- Founded
- IFRX 2007
- NNBR 1980
- Country
- IFRX Germany
- NNBR United States
- Employees
- IFRX N/A
- NNBR N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- NNBR Industrial Machinery/Components
- Sector
- IFRX Health Care
- NNBR Industrials
- Exchange
- IFRX Nasdaq
- NNBR Nasdaq
- Market Cap
- IFRX 143.7M
- NNBR 132.4M
- IPO Year
- IFRX 2017
- NNBR 1994
- Fundamental
- Price
- IFRX $2.47
- NNBR $2.77
- Analyst Decision
- IFRX Strong Buy
- NNBR
- Analyst Count
- IFRX 1
- NNBR 0
- Target Price
- IFRX $8.00
- NNBR N/A
- AVG Volume (30 Days)
- IFRX 174.5K
- NNBR 1.5M
- Earning Date
- IFRX 11-08-2024
- NNBR 03-10-2025
- Dividend Yield
- IFRX N/A
- NNBR N/A
- EPS Growth
- IFRX N/A
- NNBR N/A
- EPS
- IFRX N/A
- NNBR N/A
- Revenue
- IFRX $187,930.00
- NNBR $470,310,000.00
- Revenue This Year
- IFRX $392.79
- NNBR N/A
- Revenue Next Year
- IFRX $156.76
- NNBR $0.69
- P/E Ratio
- IFRX N/A
- NNBR N/A
- Revenue Growth
- IFRX 177.12
- NNBR N/A
- 52 Week Low
- IFRX $1.17
- NNBR $2.38
- 52 Week High
- IFRX $2.82
- NNBR $5.40
- Technical
- Relative Strength Index (RSI)
- IFRX 53.59
- NNBR 40.50
- Support Level
- IFRX $2.16
- NNBR $2.56
- Resistance Level
- IFRX $2.65
- NNBR $4.67
- Average True Range (ATR)
- IFRX 0.23
- NNBR 0.36
- MACD
- IFRX -0.01
- NNBR -0.01
- Stochastic Oscillator
- IFRX 52.54
- NNBR 20.09
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About NNBR NN Inc.
NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets. It also operates in China, Mexico, Brazil, Germany, and other countries.